Adoptive cell therapy in patients with solid malignancies
Malekzadeh received her medical degree from the University of Arizona College of Medicine – Tucson. During her surgical training at Eastern Virginia Medical School, she completed a immunotherapy/surgical oncology research fellowship under Steven Rosenberg, MD, PhD, at the Surgery Branch of the National Cancer Institute.
As a immunotherapy fellow, she was extensively involved in clinical trials, treating patients with therapeutic cancer vaccines, immune checkpoint modulation and adoptive cell therapies. As a research fellow, she initiated a novel hypothesis-driven line of investigation analyzing the immunogenicity of TP53 mutations in patients with solid malignancies. Her contribution resulted in a clinical trial investigating the role of adoptive cell therapy in TP53 mutation reactive T cells in patients with metastatic epithelial cancers.
Overall Series Objectives:
- Incorporate into practice intraoperative teaching and feedback to improve operative performance.
- Incorporate cutting-edge surgical techniques and patient management strategies.
- Incorporate into practice results from recent randomized-controlled trials/studies.
- Communicate operative knowledge effectively to peers.
The University of Arizona College of Medicine – Tucson is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The University of Arizona College of Medicine – Tucson designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement(s): All Faculty, CME Planning Committee Members and the CME Office Reviewers have disclosed that they have no financial relationships with commercial interests that would constitute a conflict of interest concerning this CME activity.